1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity
Introduction & Objective: MASH is associated with metabolic syndrome; insulin resistance is a key driver of the disease. Advanced fibrosis (F3/F4) is the strongest predictor of major liver-related outcomes. We aimed to evaluate whether the level of fasting insulin (FI) predicts the histological...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 73 |
| creator | HARRISON, STEPHEN A. DUBOURG, JULIE JEANNIN, SOPHIE COLCA, JERRY R. RATZIU, VLAD |
| description | Introduction & Objective: MASH is associated with metabolic syndrome; insulin resistance is a key driver of the disease. Advanced fibrosis (F3/F4) is the strongest predictor of major liver-related outcomes. We aimed to evaluate whether the level of fasting insulin (FI) predicts the histological severity of MASH.
Methods: Using the EMMINENCE trial (NCT02784444), we examined patients with liver histology and FI data. 393 patients with available data were divided into 3 groups according to the FI tertiles: lower, ≤ 15.11 mIU/L; middle, 15.16 - 24.23 mIU/L; upper ≥ 24.25 mIU/L. Logistic regressions were performed to predict histological severity.
Results: The upper tertile of FI was associated with a higher histological severity (fibrosis and hepatocyte ballooning, table). This was consistent with more severe patient characteristics such as higher liver enzymes, triglycerides, fibrosis biomarkers, HbA1c, and liver stiffness measurement (Table). The upper tertile was predictive of advanced fibrosis and ballooning in univariate analysis (p |
| doi_str_mv | 10.2337/db24-1582-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3111274551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111274551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c641-69ecb661af6018ec6002eeb2ece0f6053109a6abb80efd4aaec834ee74e8fe6d3</originalsourceid><addsrcrecordid>eNotkM9KAzEQh4MoWKsnXyDgRZHV_NnN7nor1dpCi4X24C1ks7OaUpOaZIW9-Q6-oU_ilsrADL_hYwY-hC4puWOc5_d1xdKEZgVLlkdoQEteJpzlr8doQAhlCc3L_BSdhbAhhIi-Bqg70A94okI09g3PbGi3xmIVsLJ9qmEHfbMRLz3URkfnsWvwAqKq3NZo_NiFprU6Gmd_v39GIThtVIQaryKo6N5hp6KJJuDrxWg1vcEr-AJvYneOThq1DXDxP4doPXlaj6fJ_OV5Nh7NEy1SmogSdCUEVY0gtAAtCGEAFQMNpF9lnJJSCVVVBYGmTpUCXfAUIE-haEDUfIiuDmd33n22EKLcuNbb_qPklFKWp1lGe-r2QGnvQvDQyJ03H8p3khK5Vyv3auVellzyP--sbhc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111274551</pqid></control><display><type>article</type><title>1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>HARRISON, STEPHEN A. ; DUBOURG, JULIE ; JEANNIN, SOPHIE ; COLCA, JERRY R. ; RATZIU, VLAD</creator><creatorcontrib>HARRISON, STEPHEN A. ; DUBOURG, JULIE ; JEANNIN, SOPHIE ; COLCA, JERRY R. ; RATZIU, VLAD</creatorcontrib><description>Introduction & Objective: MASH is associated with metabolic syndrome; insulin resistance is a key driver of the disease. Advanced fibrosis (F3/F4) is the strongest predictor of major liver-related outcomes. We aimed to evaluate whether the level of fasting insulin (FI) predicts the histological severity of MASH.
Methods: Using the EMMINENCE trial (NCT02784444), we examined patients with liver histology and FI data. 393 patients with available data were divided into 3 groups according to the FI tertiles: lower, ≤ 15.11 mIU/L; middle, 15.16 - 24.23 mIU/L; upper ≥ 24.25 mIU/L. Logistic regressions were performed to predict histological severity.
Results: The upper tertile of FI was associated with a higher histological severity (fibrosis and hepatocyte ballooning, table). This was consistent with more severe patient characteristics such as higher liver enzymes, triglycerides, fibrosis biomarkers, HbA1c, and liver stiffness measurement (Table). The upper tertile was predictive of advanced fibrosis and ballooning in univariate analysis (p<0.0001). After adjustment on HbA1c level and diabetes status, the upper tertile remains highly predictive of advanced fibrosis (p=0.001).
Conclusions: FI predicts severity of ballooning and fibrosis, independent of HbA1c level and diabetes status. Further research is warranted to assess FI as a noninvasive test to monitor MASH.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-1582-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus ; Disease resistance ; Fasting ; Fibrosis ; Insulin ; Insulin resistance ; Liver ; Metabolic syndrome ; Metabolism ; Triglycerides</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>HARRISON, STEPHEN A.</creatorcontrib><creatorcontrib>DUBOURG, JULIE</creatorcontrib><creatorcontrib>JEANNIN, SOPHIE</creatorcontrib><creatorcontrib>COLCA, JERRY R.</creatorcontrib><creatorcontrib>RATZIU, VLAD</creatorcontrib><title>1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity</title><title>Diabetes (New York, N.Y.)</title><description>Introduction & Objective: MASH is associated with metabolic syndrome; insulin resistance is a key driver of the disease. Advanced fibrosis (F3/F4) is the strongest predictor of major liver-related outcomes. We aimed to evaluate whether the level of fasting insulin (FI) predicts the histological severity of MASH.
Methods: Using the EMMINENCE trial (NCT02784444), we examined patients with liver histology and FI data. 393 patients with available data were divided into 3 groups according to the FI tertiles: lower, ≤ 15.11 mIU/L; middle, 15.16 - 24.23 mIU/L; upper ≥ 24.25 mIU/L. Logistic regressions were performed to predict histological severity.
Results: The upper tertile of FI was associated with a higher histological severity (fibrosis and hepatocyte ballooning, table). This was consistent with more severe patient characteristics such as higher liver enzymes, triglycerides, fibrosis biomarkers, HbA1c, and liver stiffness measurement (Table). The upper tertile was predictive of advanced fibrosis and ballooning in univariate analysis (p<0.0001). After adjustment on HbA1c level and diabetes status, the upper tertile remains highly predictive of advanced fibrosis (p=0.001).
Conclusions: FI predicts severity of ballooning and fibrosis, independent of HbA1c level and diabetes status. Further research is warranted to assess FI as a noninvasive test to monitor MASH.</description><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Disease resistance</subject><subject>Fasting</subject><subject>Fibrosis</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Liver</subject><subject>Metabolic syndrome</subject><subject>Metabolism</subject><subject>Triglycerides</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNotkM9KAzEQh4MoWKsnXyDgRZHV_NnN7nor1dpCi4X24C1ks7OaUpOaZIW9-Q6-oU_ilsrADL_hYwY-hC4puWOc5_d1xdKEZgVLlkdoQEteJpzlr8doQAhlCc3L_BSdhbAhhIi-Bqg70A94okI09g3PbGi3xmIVsLJ9qmEHfbMRLz3URkfnsWvwAqKq3NZo_NiFprU6Gmd_v39GIThtVIQaryKo6N5hp6KJJuDrxWg1vcEr-AJvYneOThq1DXDxP4doPXlaj6fJ_OV5Nh7NEy1SmogSdCUEVY0gtAAtCGEAFQMNpF9lnJJSCVVVBYGmTpUCXfAUIE-haEDUfIiuDmd33n22EKLcuNbb_qPklFKWp1lGe-r2QGnvQvDQyJ03H8p3khK5Vyv3auVellzyP--sbhc</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>HARRISON, STEPHEN A.</creator><creator>DUBOURG, JULIE</creator><creator>JEANNIN, SOPHIE</creator><creator>COLCA, JERRY R.</creator><creator>RATZIU, VLAD</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240614</creationdate><title>1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity</title><author>HARRISON, STEPHEN A. ; DUBOURG, JULIE ; JEANNIN, SOPHIE ; COLCA, JERRY R. ; RATZIU, VLAD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c641-69ecb661af6018ec6002eeb2ece0f6053109a6abb80efd4aaec834ee74e8fe6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Disease resistance</topic><topic>Fasting</topic><topic>Fibrosis</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Liver</topic><topic>Metabolic syndrome</topic><topic>Metabolism</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HARRISON, STEPHEN A.</creatorcontrib><creatorcontrib>DUBOURG, JULIE</creatorcontrib><creatorcontrib>JEANNIN, SOPHIE</creatorcontrib><creatorcontrib>COLCA, JERRY R.</creatorcontrib><creatorcontrib>RATZIU, VLAD</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HARRISON, STEPHEN A.</au><au>DUBOURG, JULIE</au><au>JEANNIN, SOPHIE</au><au>COLCA, JERRY R.</au><au>RATZIU, VLAD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-14</date><risdate>2024</risdate><volume>73</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Introduction & Objective: MASH is associated with metabolic syndrome; insulin resistance is a key driver of the disease. Advanced fibrosis (F3/F4) is the strongest predictor of major liver-related outcomes. We aimed to evaluate whether the level of fasting insulin (FI) predicts the histological severity of MASH.
Methods: Using the EMMINENCE trial (NCT02784444), we examined patients with liver histology and FI data. 393 patients with available data were divided into 3 groups according to the FI tertiles: lower, ≤ 15.11 mIU/L; middle, 15.16 - 24.23 mIU/L; upper ≥ 24.25 mIU/L. Logistic regressions were performed to predict histological severity.
Results: The upper tertile of FI was associated with a higher histological severity (fibrosis and hepatocyte ballooning, table). This was consistent with more severe patient characteristics such as higher liver enzymes, triglycerides, fibrosis biomarkers, HbA1c, and liver stiffness measurement (Table). The upper tertile was predictive of advanced fibrosis and ballooning in univariate analysis (p<0.0001). After adjustment on HbA1c level and diabetes status, the upper tertile remains highly predictive of advanced fibrosis (p=0.001).
Conclusions: FI predicts severity of ballooning and fibrosis, independent of HbA1c level and diabetes status. Further research is warranted to assess FI as a noninvasive test to monitor MASH.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-1582-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_3111274551 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Diabetes Diabetes mellitus Disease resistance Fasting Fibrosis Insulin Insulin resistance Liver Metabolic syndrome Metabolism Triglycerides |
| title | 1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A21%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1582-P:%20Fasting%20Insulin%20as%20an%20Independent%20Predictor%20of%20Metabolic%20Dysfunction%E2%80%93Associated%20Steatohepatitis%20(MASH)%20Severity&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=HARRISON,%20STEPHEN%20A.&rft.date=2024-06-14&rft.volume=73&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-1582-P&rft_dat=%3Cproquest_cross%3E3111274551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111274551&rft_id=info:pmid/&rfr_iscdi=true |